Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EpiPen Familiarity May Prove Tough Hurdle For Generics

Executive Summary

With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.

Advertisement

Related Content

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
Mylan Sees A Difference In Having Generic Drug User Fees
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
How to overcome the 'double-lock' barrier to entry for generic inhalers
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
Mylan’s EpiPen Defense Against Generics Focuses On Device Design

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel